Greenovation Biotech GmbH

Greenovation develops plant made next generation therapeutics using its proprietary BryoTechnology platform. The company's core competency is optimization and effective production of highly-efficient glycoproteins for the treatment of orphan diseases.

Besides developing its proprietary products for rare diseases, Greenovation offers its innovative expression technology for contract development, manufacturing and licensing.

Moss-aGal (agalsidase), a glyco-optimized form of human alpha galactosidase is Greenovation´s lead product currently in Phase I. Preclinical results suggest superiority features of moss-aGal brought by an alternative glycan mediated cellular uptake route. Additional products in Greenovation`s pipeline include improved biopharmaceuticals for aHUS and Pompe`s disease.